- Asia
- Automobile
- Bangladesh
- Banking
- Biological Inventions
- bLAWgathon
- Brand Valuation
- Business
- Company Act
- Company Law
- Competition Law
- Constitutional Law
- Consumer Law
- Copyright
- Copyright Infringement
- Copyright Litigation
- Corporate Law
- Counterfeiting
- Covid
- Design
- Digital Media
- Digital Right Management
- Educational Conferences/ Seminar
- Fashion Law
- FERs
- Foreign Law
- Gaming Industry
- GDPR
- GIg Economy
- Hi Tech Patent Commercialisation
- Hi Tech Patent Litigation
- IBC
- India
- Indonesia
- Intellectual Property
- Intellectual Property Protection
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Khadi Industries
- labour Law
- Legal Issues
- Licensing
- Live-in relationships
- Lok Sabha Bill
- Media & Entertainment Law
- Member of Parliament
- Myanmar
- NCLT
- NEPAL
- News & Updates
- Online Gaming
- Patent Act
- Patent Commercialisation
- Patent Fess
- Patent Filing
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Marketing
- Patent Opposition
- Patent Rule Amendment
- Patents
- pharma
- Pharma- biotech- Patent Commercialisation
- Pharma/Biotech Patent Litigations
- Pollution
- Protection of SMEs
- Section 3(D)
- Signapore
- Social Media
- Sports Law
- Stamp Duty
- Stock Exchange
- TAX
- Technology
- Telecom Law
- Telecommunications
- Thailand
- Trademark
- Trademark Infringement
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
IIPRD assists Venus Remedies in Successful Technology Out-licensing of Potentox to Adcock, South Africa
Venus Remedies Ltd. has successfully out-licensed its new generation antibiotic drug Potentox to Adcock Ingram Ltd. in South Africa earlier this year. Potentox is a Fixed Dose Combination (FDC) of Cefepime Hydrochloride & Amikacin Sulphate developed by Venus Remedies Ltd., indicated for treatment of Nosocomial Pneumonia & Febrile Neutropenia and available as dry powder for … Continue reading IIPRD assists Venus Remedies in Successful Technology Out-licensing of Potentox to Adcock, South Africa
Read more »Three-Days International Symposium on Patent Portfolio Management Strategies for IP Groups & R&D Scientists, Patent Agents and Attorneys of Pharmaceutical, Biotech, Chemical & Drug Industries
We are happy to inform you all that IIPRD and Khurana & Khurana, in association with Sughrue Mion (US), Schoen & Partners (EP), and Marietti Gislon S.R.L are holding their annual International Patent Symposium covering all major and relevant Pharmaceutical/Biotechnology Related Patent issues in the month of September, 2013 in India. The Three-Days International Symposium … Continue reading Three-Days International Symposium on Patent Portfolio Management Strategies for IP Groups & R&D Scientists, Patent Agents and Attorneys of Pharmaceutical, Biotech, Chemical & Drug Industries
Read more »New Guidelines for Computer Implmented Inventions. Are we still clear on what is Statutory?
It was on 8’th August 2013 that the Patent Office, based on feedback from numerous stakeholders, came out with yet another draft of guidelines on subject matters that relate to Computer Implemented Inventions, interchangeably also referred to as Computer Related Inventions (CRI) hereinafter. The mandate of the instant article is not to assess or question … Continue reading New Guidelines for Computer Implmented Inventions. Are we still clear on what is Statutory?
Read more »GSK’s patent on lapatinib ditosylate revoked by IPAB
8th August, 2013 - 9:36 am
Categories:
IP Practice in India
Pharma/Biotech Patent Litigations
0 Comments
GSK’s granted patent IN221171 (‘171) on lapatinib ditosylate (marketed as Tykerb), a tyrosine kinase inhibitor for treating breast cancer, was revoked by IPAB by its order of 27th July, 2013. A revocation application was filed by Fresenius Kabi Oncology Limited. The patent is revoked on ground of non-compliance with S.3d alone on basis of no … Continue reading GSK’s patent on lapatinib ditosylate revoked by IPAB
Read more »